Merck
  • A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.

A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.

Annals of the Royal College of Surgeons of England (2014-05-02)
S J Ford, M R Bedford, W Pang, A Wood, T Iqbal, C Tselepis, O Tucker
RESUMO

The incidence of oesophageal adenocarcinoma (OAC) is rising dramatically and overall survival remains extremely poor. Iron has been shown to potentiate tumourigenesis in OAC, and iron chelation therapy demonstrates promise in vivo as an adjunct to neoadjuvant and palliative chemotherapy. OAC, however, has traditionally been associated with iron deficiency anaemia. The aim of this study was therefore to formally quantify the iron status of OAC patients in order to guide the design of future clinical trials involving iron chelation therapy. Demographic and cancer specific data were collected prospectively from all patients presenting with OAC and gastric adenocarcinoma (GAC). Patients had haemoglobin, serum iron, serum ferritin and serum transferrin receptor (sTfR) levels measured to assess systemic iron status. In addition, the sTfR/log ferritin (sTfR-F) index was calculated. Average haemoglobin, serum iron, serum ferritin, sTfR and sTfR-F index values for all patients presenting with OAC were within normal sex specific reference ranges. No statistical difference in iron status was observed between OAC patients presenting with resectable and advanced OAC. Patients with OAC are relatively iron replete compared with those presenting with GAC. Iron parameters were not significantly altered by standard neoadjuvant chemotherapy. Patients presenting with resectable or advanced OAC could be considered as candidates for a clinical trial of iron chelation therapy as an addition to standard neoadjuvant or palliative treatments.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Iron, ≥99%, reduced, powder (fine)
Sigma-Aldrich
Carbonyl iron, ≥97% Fe basis
Sigma-Aldrich
Ferritin from equine spleen, Type I, saline solution
Sigma-Aldrich
Iron, granular, 10-40 mesh, >99.99% trace metals basis
Sigma-Aldrich
Iron, puriss. p.a., carbonyl-Iron powder, low in magnesium and manganese compounds, ≥99.5% (RT)
Sigma-Aldrich
Iron, chips, 99.98% trace metals basis
Sigma-Aldrich
Iron, foil, thickness 0.1 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Ferritin from human liver, Type IV, 10 μg/mL
Sigma-Aldrich
Iron, wire, diam. 1.0 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Iron, foil, thickness 0.25 mm, ≥99.99% trace metals basis
Sigma-Aldrich
Ferritin from human spleen, Type V, 10 μg/mL in 0.15 M NaCl, 10 mM Tris, pH 8.0, containing 0.1% sodium azide
Iron, rod, 100mm, diameter 100mm, as drawn, armcO« soft ingot 99.8%
Iron, IRMM®, certified reference material, 0.5 mm wire
Iron, foil, 100x100mm, thickness 0.125mm, as rolled, 99.99+%
Iron, rod, 100mm, diameter 2.0mm, as drawn, 99.95%
Iron, foil, 15mm disks, thickness 0.0125mm, 99.99+%
Iron, foil, 10mm disks, thickness 0.01mm, 99.85%
Iron, rod, 1000mm, diameter 2.0mm, as drawn, 99.95%
Iron, foil, 4mm disks, thickness 0.005mm, 99.85%
Iron, rod, 500mm, diameter 4.8mm, as drawn, 98+%
Iron, foil, 25mm disks, thickness 0.003mm, 99.85%
Iron, foil, 300x300mm, thickness 3.0mm, as rolled, 99.5%
Iron, foil, 15mm disks, thickness 0.004mm, 99.99+%
Iron, foil, 150x150mm, thickness 0.125mm, hard, 99.5%
Iron, foil, 15mm disks, thickness 0.008mm, 99.85%
Iron, foil, light tested, 100x100mm, thickness 0.015mm, 99.85%
Iron, foil, not light tested, 100x100mm, thickness 0.015mm, 99.99+%
Iron, rod, 1000mm, diameter 9.5mm, as drawn, 98+%
Iron, foil, 150x150mm, thickness 1.5mm, as rolled, 99.5%
Iron, rod, 500mm, diameter 19.0mm, as drawn, 98+%